- Semaglutide2019 | First Faculty of Medicine
- Semaglutide and atherosclerosis: the present knowledge and perspectives2023 | First Faculty of Medicine
- Semaglutide in the treatment of type 2 diabetes mellitus2019 | First Faculty of Medicine
- Semaglutide: a simple solution of a common barrier in the intensification of diabetes therapy2021 | Publication without faculty affiliation
- Semaglutide: an effective antidiabetic agent with proven cardiovascular benefit in clinical practice2020 | First Faculty of Medicine
- Oral semaglutid in the therapy of type 2 diabetes mellitus2021 | First Faculty of Medicine
- Oral semaglutide in the treatment of type 2 diabetes2020 | First Faculty of Medicine
- Cardiovascular safety of liraglutide and semaglutide. Clinical comments to the discussed trials LEADER and SUSTAIN 62016 | Second Faculty of Medicine
- Sitagliptin versus semaglutide in type 2 diabetes mellitus2020 | Second Faculty of Medicine
- Semaglutid 1x denně prokázal větší účinnost než liraglutid2019 | First Faculty of Medicine
- Research Report University Hospital clinical trial NN9924-4079Publication without faculty affiliation
- Perorální forma semaglutidu - nová možnost v terapii diabetes mellitus 2. typu2021 | First Faculty of Medicine
- Semaglutid - zlom v léčbě obezity2020 | First Faculty of Medicine
- Anti-obesity drug with exceptional benefit for preventive cardiology: current results of the SELECT trial2023 | First Faculty of Medicine
- Liraglutid a semaglutid v léčbě obezity2021 | First Faculty of Medicine
- Novel drugs in pharmacotherapy of obesity2021 | First Faculty of Medicine
- Semaglutid – látka mnoha tváří a přínosů2023 | First Faculty of Medicine
- Co přinesl rok 2022 v diabetologii2023 | First Faculty of Medicine
- Promising molecules for treatment of hyperglycemia in patients with type 2 diabetes2016 | Second Faculty of Medicine
- Inkretinová analoga v léčbě obezity v současnosti2022 | First Faculty of Medicine
- Semaglutid vs. sitagliptin u pacientů s diabetes mellitus 2. typu - studie PIONEER 3 a 72021 | First Faculty of Medicine
- A new antidiabetic drug in sight2022 | Publication without faculty affiliation
- The effect of GLP‑1 receptor agonists on improving glucose control and decreasing body weight: results of direct comparative trials and network meta‑analysis2022 | First Faculty of Medicine
- Inkretinová analoga2018 | First Faculty of Medicine
- Máme pacientům co nabídnout v léčbě obezity?2019 | First Faculty of Medicine
- Nové molekuly pro terapii diabetu vyvíjené inovativními farmaceutickými společnostmi2017 | Second Faculty of Medicine
- Komentář ke studii (Uspořádání a výchozí charakteristiky účastníků kardiovaskulární studie REWIND s dulaglutidem)2018 | First Faculty of Medicine
- komentář ke studii2017 | Second Faculty of Medicine
- Praktický návod, jak dnes užívat antiobezitika2021 | First Faculty of Medicine
- An overview of current therapy options of non-alcoholic fatty liver disease2022 | First Faculty of Medicine